1. Home
  2. EXAS vs TAP Comparison

EXAS vs TAP Comparison

Compare EXAS & TAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • TAP
  • Stock Information
  • Founded
  • EXAS 1995
  • TAP 1873
  • Country
  • EXAS United States
  • TAP United States
  • Employees
  • EXAS N/A
  • TAP N/A
  • Industry
  • EXAS Medical Specialities
  • TAP Beverages (Production/Distribution)
  • Sector
  • EXAS Health Care
  • TAP Consumer Staples
  • Exchange
  • EXAS Nasdaq
  • TAP Nasdaq
  • Market Cap
  • EXAS 11.6B
  • TAP 12.6B
  • IPO Year
  • EXAS N/A
  • TAP N/A
  • Fundamental
  • Price
  • EXAS $59.25
  • TAP $59.16
  • Analyst Decision
  • EXAS Strong Buy
  • TAP Hold
  • Analyst Count
  • EXAS 16
  • TAP 14
  • Target Price
  • EXAS $72.80
  • TAP $62.00
  • AVG Volume (30 Days)
  • EXAS 2.2M
  • TAP 1.7M
  • Earning Date
  • EXAS 11-05-2024
  • TAP 02-11-2025
  • Dividend Yield
  • EXAS N/A
  • TAP 2.97%
  • EPS Growth
  • EXAS N/A
  • TAP 275.92
  • EPS
  • EXAS N/A
  • TAP 4.42
  • Revenue
  • EXAS $2,692,328,000.00
  • TAP $11,682,200,000.00
  • Revenue This Year
  • EXAS $11.81
  • TAP $0.11
  • Revenue Next Year
  • EXAS $11.41
  • TAP N/A
  • P/E Ratio
  • EXAS N/A
  • TAP $13.41
  • Revenue Growth
  • EXAS 11.91
  • TAP 1.23
  • 52 Week Low
  • EXAS $40.62
  • TAP $49.19
  • 52 Week High
  • EXAS $79.62
  • TAP $69.18
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 48.86
  • TAP 44.02
  • Support Level
  • EXAS $61.28
  • TAP $58.78
  • Resistance Level
  • EXAS $62.15
  • TAP $62.13
  • Average True Range (ATR)
  • EXAS 2.02
  • TAP 1.28
  • MACD
  • EXAS 0.15
  • TAP -0.43
  • Stochastic Oscillator
  • EXAS 3.39
  • TAP 12.54

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About TAP Molson Coors Beverage Company Class B

Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the us, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the us, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.

Share on Social Networks: